Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
Dr. Debra Patt highlights the FDA’s swift approval of Enhertu for HER2-low metastatic breast cancer, stressing rapid patient access.
August 6, 2022
Care Advancements
ByDebra Patt, M.D., Ph.D., MBA
Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, discussed the rapid approval of Enhertu in HER2-low metastatic breast cancer by the FDA – underscoring the urgency to bring the transformational medicine to patients as quickly as possible.
